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Background
The Saline versus Albumin Fluid Evaluation study suggested that patients with traumatic brain injury resuscitated with 
albumin had a higher mortality rate than those resuscitated with saline. The SAFE investigators conducted a post hoc 
follow-up study of patients with traumatic brain injury who were enrolled in the study.
Methods
Objective: The aims of the study were to document baseline characteristics that are known to infl  uence outcomes 
from traumatic brain injury in the albumin and saline groups and to compare death and functional neurologic 
outcomes in the two groups 24 months after randomization.
Design: A post hoc follow-up study of patients with traumatic brain injury who were enrolled in the SAFE study.
Setting: Intensive care units of 16 academic tertiary hospitals in Australia and New Zealand.
Subjects: 460 patients 18 years or older with traumatic brain injury (i.e., a history of trauma, evidence of head trauma 
on a computed tomographic [CT] scan, and a score of ≤13 on the Glasgow Coma Scale [GCS]).
Intervention: 231 (50.2%) received four percent albumin and 229 (49.8%) received saline.
Outcomes: The primary outcome measures were the mortality rate and functional neurologic outcome 24 months 
after randomization. Multivariate logistic-regression was used to adjustment for baseline covariates known to be 
associated with increased mortality from traumatic brain injury (age older than 60 years, GCS score of 8, systolic 
pressure of <90 mm Hg, and traumatic subarachnoid hemorrhage). Analyses were conducted in all patients and in 
subgroups according to severity of traumatic brain injury.
Results
The subgroup of patients with GCS scores of 3 to 8 were classifi  ed as having severe brain injury (160 [69.3%] in the 
albumin group and 158 [69.0%] in the saline group). Demographic characteristics and severity of brain injury were 
similar at baseline. At 2 years, 71 of 214 patients in the albumin group (33.2%) had died, as compared with 42 of 206 
in the saline group (20.4%) (relative risk, 1.63; 95% confi  dence interval [CI], 1.17 to 2.26; P=0.003). Among patients with 
severe brain injury, 61 of 146 patients in the albumin group (41.8%) died, as compared with 32 of 144 in the saline 
group (22.2%) (relative risk, 1.88; 95% CI, 1.31 to 2.70; P<0.001); among patients with GCS scores of 9 to 12, death 
occurred in 8 of 50 patients in the albumin group (16.0%) and 8 of 37 in the saline group (21.6%) (relative risk, 0.74; 
95% CI, 0.31 to 1.79; P=0.50).
Conclusions
In this post hoc study of critically ill patients with traumatic brain injury, fl  uid resuscitation with albumin was 
associated with higher mortality rates than was resuscitation with saline. (Current Controlled Trials number, 
ISRCTN76588266.)
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Traumatic brain injury (TBI) is devastating with catas-
trophic consequences. Early recognition of injury and 
prompt delivery of focused care of the traumatic brain 
injured patient is essential to patient outcome. Resusci-
tative ﬂ  uids are one of the cornerstones in the manage-
ment of the critically ill. For years, there has been debate 
regarding the optimal choice of ﬂ  uids in the traumatic 
brain injured population. Central to this debate has been 
the relative merits of albumin versus saline. In 1998, a 
meta-analysis by the Cochrane Injuries Group concluded 
that the administration of albumin containing ﬂ  uids to 
the critically ill increased absolute risk of death by 6% [2]. 
Following this ﬁ  nding, uncertainty about the best choice 
of ﬂ  uids persisted due to a lack of adequately powered 
randomized, controlled trials. Subsequently, a large, multi-
center trial, the Saline versus Albumin Fluid Evaluation 
(SAFE) trial, found no diﬀ  erence in 28-day mortality for 
critically ill patients resuscitated with albumin versus 
saline [3]. Subgroup analysis of SAFE participants 
suggested an increased number of deaths among patients 
with TBI who received albumin. Th   e clinical signiﬁ  cance 
of these ﬁ  ndings were unclear due to lack of baseline data 
about factors known to be associated with increased 
mortality from traumatic brain injury and concern about 
the use of short-term outcomes when outcomes between 6 
and 24 months are recommended after TBI.
To determine the potential signiﬁ  cance of this ﬁ  nding, 
the SAFE study investigators undertook this post-hoc 
analysis (SAFE-TBI) [1], which included obtaining rele-
vant baseline characteristics from case report forms, 
clinical records, and CT scans, and a determination of 
vital status and functional neurologic outcomes 24 months 
after randomization. Th  e authors compared mortality 
and functional neurologic outcomes in patients with TBI 
in the saline and albumin groups at two years after 
randomization and used multivariate logistic-regression 
to adjustment for baseline covariates known to be 
associated with increased mortality from traumatic brain 
injury. Analyses were conducted in all patients and in 
subgroups according to severity of traumatic brain injury. 
Th  e authors found that resuscitation with albumin was 
associated with higher mortality rates. Furthermore, 
there were signiﬁ  cantly fewer favorable neurologic out-
comes at 24 months in the albumin group. However, this 
diﬀ  erence appeared to be due to the greater mortality 
rates in the albumin group, since functional outcomes in 
survivors were similar between groups. When stratiﬁ  ed 
by TBI severity, the increase in unfavorable outcomes 
seen with albumin were only signiﬁ  cant in those with 
severe TBI (GCS score of 3-8).
SAFE-TBI is a well done post-hoc analysis. Th  e two 
groups were well balanced in terms of baseline 
characteristics, the follow-up at two years was excellent 
(90%), the results were very consistent, the diﬀ  erences in 
mortality were quite large, and the conclusion drawn was 
consistent with the ﬁ  ndings. Th   e study has a few weak-
nesses that deserve mention. Because it is a post-hoc 
subgroup analysis, it can only suggest associations and 
cannot prove a cause-eﬀ  ect relationship between albumin 
and mortality due to the potential for chance subgroup 
ﬁ  ndings. Th   ough patients were randomized and investi-
gators blinded to which ﬂ  uid patients were receiving, it 
remains possible that there were diﬀ   erences in the 
clinical management of their TBI, something which the 
authors were unable to capture.
Based on the results of SAFE-TBI and other studies, the 
Cochrane group concluded that there is no evidence 
from randomized controlled trials in critically ill or 
trauma patients that resuscitation with colloids compared 
to crystalloids reduces the risk of death [4]. Notwith-
standing, recent studies of experimental TBI in mouse 
models have renewed interest in the use of colloids [5,6]. 
Baker and colleagues demonstrated enhanced electro-
physio  logical recovery with albumin versus saline resus-
citation [5]. Exo and colleagues found that colloids 
exhibited favorable eﬀ   ects on acute resuscitation 
parameters versus hypertonic saline or lactated ringers 
and that colloid use did not increase hippocampal 
neuronal death [6]. To explore the eﬃ   cacy of albumin as 
a neuroprotective agent for TBI in humans, a randomized 
controlled trial, Albumin for Intracerebral Hemorrhage 
Intervention (ACHIEVE), is currently underway [7].
Recommendation
Th  e  ﬁ  ndings of SAFE-TBI are another important addition 
to the unfavorable existing literature concerning the 
superiority of colloid over crystalloid. Based on the 
current evidence and the fact that albumin is far more 
expensive than crystalloids, it seems reasonable to avoid 
the use of albumin when resuscitating patients with 
severe TBI. Adequately powered randomized controlled 
trials will be needed to deﬁ  nitely answer the question of 
which resuscitation ﬂ  uid to use in TBI.
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